GENVIVO

GENVIVO specializes in pre-clinical assessments and evaluation of novel compounds or protein based biologics as therapeutic agents for the treatment of diabetes, inflammation, cancer, neurological and metabolic diseases. The company's senior leadership has over 30 years of drug discovery experience in small molecules and  recombinant protein biologics utilizing conventional, gene knock-out, orthotopic, xenograft and transgenic animal models.  GENVIVO offers over 100 animal models along with complimentary services such as cell based preclinical efficacy testing, pharmacokinetics studies, pharmacodynamics, and pre-GLP toxicology testing in vitro and in vivo.  GENViVO currently provides services in three major areas: Efficacy, Pharmacokinetics and Toxicology.

Efficacy Models

Over 100 animal models for various diseases

• Diabetes Type II
  

• Diabetes Type I
  

• Obesity
  

• Hyperlipidemia
  

• Rheumatoid Arthritis
  

• Inflammatory Bowl Disease
  

• Osteoarthritis
  

• Psoriasis
  

• Multiple Sclerosis
  

• Pain
  

• Schizophrenia
  

• Parkinson’s
  

• Alzheimer
  

• Cardiovascular
  

• Cancer
  

Pharmacokinetics Studies

NRL provides fast track PK studies in rodents (rats and mice).  Our pre-GLP pharmacokinetic studies can save time and money of picking the right molecule for development. At present the following PK related services are provided by NRL:

• PK studies in rats and mice
  

• Multiple  routes of Administration
  

• Bioavailability comparison among analogs
  

• PK comparison with different routes
  

• Absolute and relative bioavailability of drugs
  

• PK with alternative formulations
  

• PK studies comparison in normal and disease-induced animals
  

Pre-GLP Toxicology Studies

• Maximum Tolerated Dose (MTD) Studies
  

• Acute Single Dose Toxicity Studies
  

• Repeated Dose Toxicity Studies
  

• Sub-Chronic Toxicity Studies
  

• Chronic Toxicity Studies
  

• Toxicokinetic Studies
  

• Cytotoxicity Studies
  

• Genotoxicity Studies
  

• Cell Based Toxicity Assays
  

• Dose Response Toxicity Assays
  

• Liver Hepatocytes Toxicity Assays
  

• Tissue Specific Toxicity Assays
  

• Ex-Vivo Toxicity Assays
  

Tel:

Fax:

www.nagresearchlabs.com

510-770-1175

510-770-1635

Next Generation of Discovery, Development and Commercialization

Next Generation of Discovery, Development and Commercialization

U.S. Corporate Office

Bayside Technology Park

46500 Fremont Blvd. #704-706

Fremont,  CA 94538  USA